Who is sponsoring NCT05141058?

NCT05141058 is sponsored by Children's National Research Institute.

What drugs are being tested in NCT05141058?

Interventions in NCT05141058: Coronavirus-specific T cell (CST).

What condition does NCT05141058 study?

NCT05141058 studies SARS-CoV-2 Infection.

Is NCT05141058 still recruiting?

NCT05141058 is currently recruiting now. Last updated 12 March 2026.

Last reviewed 2026-03-12 · How we verify

NCT05141058: TONI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

Recruiting now Phase 1 Last updated 12 March 2026

What this trial tests

Phase 1 trial testing Coronavirus-specific T cell (CST) in SARS-CoV-2 Infection in 24 participants. Currently enrolling.

Timeline

19 October 2021

Primary endpoint
1 November 2028

15 December 2029

Quick facts

Lead sponsor	Children's National Research Institute
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	24
Start date	19 October 2021
Primary completion	1 November 2028
Estimated completion	15 December 2029
Sites	2 locations across United States

Drugs / interventions tested

Coronavirus-specific T cell (CST) — full drug profile →

Conditions studied

SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →

Sponsor

Children's National Research Institute

Who can join

Adults 2 to 80, any sex, with SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after HSCT). In this dose escalation trial, three doses (1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and \<80 years) HSCT recipients (Arm A) and two arms for pediatric (≥12 years of age and \<18 years; ≥2 years and \<12 years) HSCT recipients (Arm B and Arm C, respectively), and defined dose escalations in each study arm. The study agent will be assessed for safety (stopping rules defined) and antiviral activity.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cellular therapies for the treatment and prevention of SARS-CoV-2 infection.
Conway SR, Keller MD, Bollard CM. · · 2022 · cited 16× · PMID 35240679 · DOI 10.1182/blood.2021012249
Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond.
Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, et al · · 2023 · cited 11× · PMID 36698615 · DOI 10.1097/hs9.0000000000000809
Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities.
Nova Z, Zemanek T, Botek N. · · 2022 · cited 1× · PMID 36499448 · DOI 10.3390/ijms232315122

Verify or expand the search:

Other recruiting trials for SARS-CoV-2 Infection

Currently open trials in the same condition.

NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting
NCT04636697 — Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults · Phase 2, PHASE3 · active not recruiting

Other Children's National Research Institute trials

Trials by the same sponsor.

NCT07336264 — Characterization of Acute Pain · recruiting
NCT06938542 — Palliative Care Needs of Children With Rare Diseases and Their Families · NA · enrolling by invitation
NCT06618027 — Pragmatic Clinic-Based Trial of a Mindfulness Based Intervention for Mood Concerns in Youth With Type 1 Diabetes · NA · recruiting
NCT06770010 — Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease · NA · recruiting
NCT06623981 — The Exhale Study: Treating Maternal Depression in an Urban Pediatric Asthma Clinic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05141058 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's National Research Institute
Last refreshed: 12 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05141058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing